Immunological recovery with BIC/FTC/TAF: CD4 T-cell count and CD4/CD8 ratio as markers of response

The CD4/CD8 ratio is a crucial marker of immune dysregulation, immune senescence, and inflammation, predicting outcomes such as non-AIDS conditions and mortality. A low CD4/CD8 ratio is common in late HIV diagnoses, which remain frequent in Italy, where 58% of new cases occur with advanced immune su...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New microbiologica Ročník 48; číslo 1; s. 1
Hlavní autoři: Bono, Valeria, Marchetti, Giulia C
Médium: Journal Article
Jazyk:angličtina
Vydáno: Italy 01.03.2025
Témata:
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
CD4-CD8 Ratio
Emtricitabine - therapeutic use
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
HIV-1 - drug effects
Humans
Tenofovir - analogs & derivatives
Tenofovir - therapeutic use
Immunological recovery
BIC/FTC/TAF
CD4/CD8 ratio
CD4 T-cell count
ISSN:1121-7138
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The CD4/CD8 ratio is a crucial marker of immune dysregulation, immune senescence, and inflammation, predicting outcomes such as non-AIDS conditions and mortality. A low CD4/CD8 ratio is common in late HIV diagnoses, which remain frequent in Italy, where 58% of new cases occur with advanced immune suppression (CD4 <350 cells/μL). Recent advancements in cART, particularly bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), have demonstrated superior efficacy in restoring immune function, especially in late-stage HIV. BIC/FTC/TAF offers high virological suppression, durable immune reconstitution, and a favorable safety profile. Comparative studies highlight its advantages in improving CD4 counts, reducing HIV RNA, and mitigating inflammatory markers, suggesting potential cardiovascular benefits. These findings position BIC/FTC/TAF as an effective option for advanced HIV treatment, contributing to better immune recovery and reduced systemic inflammation.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1121-7138